Patterns of aspirin use in middle-aged adults: The atherosclerosis risk in communities (ARIC) study

American Heart Journal

Volumn 131, Issue 5, 1996, Pages 915-922

  Shahar, Eyal ^a,g   Folsom, Aaron R ^a   Romm, Fredric J ^b   Bisgard, Kristine M ^c   Metcalf, Patricia A ^d   Crum, Larry ^d   McGovern, Paul G ^a   Hutchinson, Richard G ^e   Heiss, Gerardo ^f  

^a UNIVERSITY OF MINNESOTA   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c KANSAS DEPARTMENT OF HEALTH AND ENVIRONMENT   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^f IL   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; NON PRESCRIPTION DRUG;

ADULT; AGING; ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY RISK; DOSE RESPONSE; FEMALE; GENDER; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACE DIFFERENCE; SMOKING;

EID: 0029866182     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(96)90173-8     Document Type: Article

References (37)

1. Lekstrom JA, Bell WR. Aspirin in the prevention of thrombosis. Medicine 1991;70:161-78.
2. Willard JE, Lange RA, Hillis LD. Current concepts: the use of aspirin in ischemic heart disease. N Engl J Med 1992;327:175-81.
3. Ridker PM, Manson JE, Gaziano M, Buring JE, Hennekens CH. Lowdose aspirin therapy for chronic stable angina: a randomized, placebocontrolled clinical trial. Ann Intern Med 1991;114:835-9.
4. Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty JE III, Schnaper HW, LeWinter MM. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration cooperative study. N Engl J Med 1983;309:396-403.
5. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
6. UK-TIA Study Group. United Kingdom transient ischemic attack (UK-TIA) aspirin trial: interim results. BMJ 1988;296:316-20.
7. Kallmann R, Nleuwenhuis HK, de Groot PG, van Gijn J, Sixma JJ. Effects of low doses of aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane production and 6-keto-PHF1a excretion in healthy subjects. Thromb Res 1987;45:355-61.
8. Steering Committee of the Physicians' Health Study Research Group. Preliminary report: findings from the aspirin component of the ongoing physicians' health study. N Engl J Med 1988;318:262-4.
9. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing physicians' health study. N Engl J Med 1989;321:129-35.
10. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, Warlow C, Hafner B, Thompson E, Norton S, Gilliland J, Doll R. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988;296:313-31.
11. Hennekens CH, Peto R, Hutchison GB, Doll R. An overview of the British and American aspirin studies [Letter]. N Engl J Med 1988; 318:923-4.
12. Manson JE, Tosteson H, Satterfield S, Hebert P, O'Connor GT, Buring JE, Hennekens CH. The primary prevention of myocardial infarction. N Engl J Med 1992;326:1406-16.
13. Buring JE, Hennekens CH for the Women's Health Study Research Group. The Women's Health Study: summary of the study design. J Myocard Ischem 1992;4:27-9.
14. U.S. Preventive Services Task Force. Aspirin prophylaxis. In: Fisher M, ed. Guide to clinical preventive services: an assessment of the effectiveness of 169 interventions. Baltimore, Md.: Williams & Wilkins, 1989:381-4.
15. Dalen JE. An apple a day or an aspirin a day? Arch Intern Med 1991; 151:1066-9.
16. Canadian Task Force on the Periodic Health Examination. Periodic health examination, 1991 update: 6. acetylsalicylic acid and the primary prevention of cardiovascular disease. Can Med Assoc J 1991;145:1091-5.
17. Chesebro JH, Opie LH, Fuster V. The recent trials for aspirin in the prevention of cardiovascular mortality. Cardiovasc Drug Ther 1989; 3:353-4.
18. Jonas, S. The physicians' health study: a neurologist's concern. Arch Neurol 1990;47:1352-4.
19. The ARIC Investigators. The atherosclerosis risk in communities (ARIC) study: design and objectives. Am J Epidemiol 1989;129:687-702.
20. Jackson R, Chambless LE, Yang K, Byrne T, Watson R, Folsom A, Shahar E, Kalsbeek W. Characteristics of respondents and nonrespondents in a multicenter cohort study of atherosclerotic disease: the ARIC study. J Clin Epidemiol In press.
21. Rose GA, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular Survey Methods. 2nd ed. Geneva: World Health Organization, 1982.
22. SAS/STAT user's guide, version 6. Cary, NC: SAS Institute, 1989.
23. Mantel N. Chi-square tests with one degree of freedom; extensions of the Mantel-Haenszel procedure. J Am Stat Assoc 1963;58:690-700.
24. Miettinen OS. Proportion of disease caused or prevented by a given exposure, trait or intervention. Am J Epidemiol 1974;99:325-32.
25. Arrowsmith JB, Kennedy DL, Kuritsky JN, Faich GA. National patterns of aspirin and Reye syndrome reporting, United States, 1980 to 1985. Pediatrics 1987;79:858-63.
26. Folsom AR, Iso H, Sprafka JM, Edlavitch SA, Luepker RV. Use of aspirin for prevention of cardiovascular disease - 1981-82 to 1985-86: the Minnesota Heart Survey. AM HEART J 1988;116:827-8.
27. Bonham GS, Leaverton PE. Use habits among adults of cigarettes, coffee, aspirin, and sleeping pills, United States, 1976. Washington, D.C.: U.S. Department of Health, Education, and Welfare, Public Health Service. Vital and Health Statistics Series 1979;10(131):1-47.
28. Mahon J, Steel K, Feagan BG, Laupacis A, Pederson LL. Use of acetylsalicylic acid by physicians and in the community. Can Med Assoc J 1991;145:1107-16.
29. Psaty BM, Lee M, Savage PJ, Rutan GH, German PS, Lyles M. Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. J Clin Epidemiol 1992;45:683-92.
30. Moss AJ, Benhorin J. Prognosis and management after a first myocardial infarction. N Engl J Med 1990;322:743-53.
31. Aspirin Myocardial Infarction Study Research Group. A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980;243:661-9.
32. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988;296:320-31.
33. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
34. Canner PL. Aspirin in coronary heart disease: comparison of six clinical trials. Isr J Med Sci 1983;19:413-23.
35. Garber CE, Carleton RA, Heller GV. Comparison of "Rose questionnaire angina" to exercise thallium scintigraphy: different findings in males and females. J Clin Epidemiol 1992;45:715-20.
36. Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau JL, Braunwald E, for the SAVE Investigators. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? N Engl J Med 1992;327:241-7.
37. Thompson PL, Parsons RW, Jamrozik K, Hockey RL, Hobbs MST, Broadhurst RJ. Changing patterns of medical treatment in acute myocardial infarction. Med J Aust 1992;157:87-92.